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Abstract (250 words)  86 
Background: Pediatric Inflammatory Bowel Disease (PIBD) is a chronic condition seen in 87 
genetically-predisposed individuals. GWAS have implicated >160 genomic loci in IBD with many 88 
genes coding for proteins in key immune pathways. This study looks at autoimmune disease burden in 89 
patients diagnosed with PIBD and interrogates exome data of a subset of patients. 90 
Methods: Patients were recruited from the Southampton Genetics of PIBD cohort. Clinical diagnosis 91 
of autoimmune disease in these individuals was ascertained from medical records. For a subset of 92 
patients with PIBD and concurrent asthma, exome data was interrogated to ascertain the burden of 93 
pathogenic variants within genes implicated in asthma. Association testing was conducted between 94 
cases and population controls using the SKAT-O test.  95 
Results: Forty-nine (28.3%) PIBD children (18.49%CD, 8.6% UC and 2 1.15% IBDU patients) had a 96 
concurrent clinical diagnosis of at least one other autoimmune disorder; asthma was the most 97 
prevalent, affecting 16.2% of the PIBD cohort. Rare and common variant association testing revealed 98 
six significant genes (p< 0.05) prior to Bonferroni adjustment. Three of these genes were previously 99 
implicated in both asthma and IBD (ZPBP2 IL1R1 and IL18R1) and three in asthma only (PYHIN1, 100 
IL2RB and GSTP1).  101 
Conclusions: One third of our cohort had a concurrent autoimmune condition. We observed higher 102 
incidence of asthma compared to the overall pediatric prevalence. Despite a small sample size, 103 
SKAT-O evaluated a significant burden of rare and common mutations in 6 genes. Variant burden 104 
suggests a systemic immune dysregulation rather than organ specific could underpin immune 105 
dysfunction for a subset of patients.  106 
 107 
Key words: Pediatric Inflammatory bowel disease, comorbidity, exome sequencing, autoimmune 108 
disorders, asthma, genetics,  109 
 110 
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Introduction 111 
Pediatric Inflammatory bowel disease (PIBD) encompasses Crohn’s disease (CD), ulcerative colitis 112 
(UC) and inflammatory bowel disease unclassified (IBDU), a group of complex and multifactorial 113 
illnesses. The etiology is complex and  likely to comprise of four key concepts: immune dysregulation, 114 
barrier dysfunction, microbial flora and a genetic predisposition
1,2
; how specific interaction between 115 
these factors leads to development of disease is poorly understood. 116 
 117 
The incidence of PIBD is increasing in Europe and North America.  Recent studies from England
3
, 118 
Scotland
4
 and Scandanvia
5
 have shown increasing incidence over the last 20 years with incidence as 119 
high as 12.8/100,000/year in Sweden
6
. This increase may be driven by lifestyle changes. The hygiene 120 
hypothesis relating to autoimmune conditions is well established in the literature and it is conceivable 121 
that altered microbial exposure in these children may have a role in development of disease
7,8
.  122 
 123 
Over the past decade, genome-wide association studies (GWAS) have substantially advanced the 124 
understanding of many complex diseases 
9
.  Since the discovery in 2001 of NOD2, the first genetic 125 
susceptibility gene for IBD
10,11
, over 160 distinct loci have been shown to have a robust association 126 
with IBD
12,1314
 However, common variation in  these genes account for only approximately one 127 
quarter of the disease heritability
15
. It is now assumed that rare variants in pathways implicated across 128 
various  autoimmune conditions may account for some of the missing heritability in IBD
16
. Various 129 
studies in adult populations have looked at the incidence of other autoimmune mediated disorders in 130 
patients suffering from IBD
17–19
. Previous studies into the co-existence of PIBD and other 131 
autoimmune disease have reported strong association between PIBD (both CD and UC) and 132 
rheumatoid arthritis, Systemic Lupus Erythematosus and hypothyroidism with a trend towards 133 
increased prevalence of other autoimmune conditions including asthma and eczema
20
. 134 
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Predisposition to IBD and other autoimmune disease has a strong genetic component and analyses of 135 
exomes of these patients may yield variations associated with both groups of disease. This study 136 
examines the autoimmune disease burden in patients diagnosed with PIBD and interrogates exome 137 
data of a subset of patients. 138 
 139 
  140 
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Materials and Methods 141 
RECRUITMENT 142 
Recruitment of children diagnosed with PIBD was through services at University Hospital 143 
Southampton (UHS). All children aged below 18 at the point of diagnosis were eligible. Diagnosis 144 
was established according to the  Porto criteria
21
. Clinical data were recorded for each patient 145 
including family history of IBD and any history of autoimmune disease
22
.  146 
 147 
PATIENT DATA EXTRACTION 148 
Data from 173 patients prospectively collected at recruitment was interrogated to identify PIBD 149 
patients with: 1) Comorbidity of other autoimmune diseases (clinician diagnosed) and; 2) positive 150 
family history of autoimmune diseases other than IBD. Medical notes were consulted for any 151 
ambiguous diagnosis and review allowed for exclusion of any unconfirmed diagnoses.  152 
 153 
DNA EXTRACTION 154 
Genomic DNA was extracted from peripheral venous blood samples collected in EDTA, using the 155 
salting out method
23
. DNA concentration was estimated using the Qubit ® 2.0 Fluorometer and A 156 
260:280 ratio calculated using a nanodrop spectrophotometer. The average DNA yield obtained was 157 
150µg/ml and approximately 20ug of DNA was used for next generation sequencing for each patient. 158 
 159 
PATIENT SELECTION   160 
Of the 28 IBD patients who had a concurrent diagnosis of asthma we selected the 18 youngest of 161 
these for exome analysis. All 18 were of white British ancestry.  162 
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EXOME DATA GENERATION AND PROCESSING 163 
Whole exome sequencing was performed using the Agilent SureSelect Human all Exon 51 Mb 164 
version 4 capture kit. The fastq raw data generated from Illumina paired-end sequencing were aligned 165 
against the human reference genome (hg19) using Novoalign (novoalign/2.08.02). Sequence coverage 166 
for each sample was calculated using the BedTools package (v2.13.2)(Supplementary table SI).  167 
SAMtools 
24
 mpileup tool (samtools/0.1.18) was used to detect variation from the mapping 168 
information to call SNPs and short INDELs from the alignment file. Variations with read depth < 4 169 
were excluded. The Phred software
25
 reads DNA sequencing trace files, calls bases, and assigns a 170 
quality value to each called base and is powered to discriminate between correct and incorrect base-171 
calls. Only good quality bases with a phred score > 20 were retained for analysis (99% base call 172 
accuracy). ANNOVAR (annovar/2013Feb21) 
26
 was applied for variant annotation against a database 173 
of  RefSeq transcripts. Resultant variants files for each subject were subjected to further in-house 174 
quality control tests to detect DNA sample contamination and ensure sex concordance by assessing 175 
autosomal and X chromosome heterozygosity. Variant sharing between all pairs of individuals was 176 
assessed to confirm sample relationships. Sample provenance was confirmed by independent 177 
genotyping of a validated SNP panel, developed specifically for exome data 
27
. 178 
 179 
GENE SELECTION 180 
The latest genome-wide meta-analysis of IBD reported 193 genes across 163 loci with statistically 181 
independent signals of association at genome-wide significance (P<5x10-8)
13
. These genes were 182 
cross-referenced with 49 genes associated with asthma identified  by linkage studies and GWAS
28
. 183 
Sixteen of these genes have been associated with both asthma and IBD (Figure 1). Gene names were 184 
cross-referenced with the HUGO webserver to confirm the approved gene symbol.  185 
 186 
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VARIANT ASSOCIATION TESTING 187 
Our findings and those of others
29,30
 indicate asthma is the most common concurrent autoimmune 188 
disease in IBD patients. For this reason we wanted to further investigate if a subset of patients with a 189 
concurrent diagnosis of both IBD and asthma present with a significant burden of mutation within 190 
known genes associated with asthma. Our modest sample size was underpowered to extend this 191 
analysis to all 193 IBD genes. 192 
To detect association between the genetic component and disease status first a single variant test and 193 
then a gene-based test (SKAT-O) were performed. In order to run these tests, genotype information 194 
(homozygous alternative, homozygous reference or heterozygous status) were retrieved using 195 
customized scripts applying samtools
24
, vcftools
31
 and bedtools
32
 packages. All variant sites across 49 196 
genes (comprising 33 genes specific to asthma and 16 genes common to both diseases) were used to 197 
generate  the variant call file (VCF)  for each of the 18 exome analyzed patients and 56 unrelated, 198 
germline controls. Our genomics bioinformatics group has a rolling database of non-IBD clinical 199 
exomes. Controls without any clinical diagnosis of autoimmune disease were selected from this in-200 
house database. 201 
Variations were further excluded based on the Hardy-Weinberg equilibrium status (p<0.001) in the 202 
control group, by using vcftools
31
. VCF files containing genotype information for all cases and 203 
controls were merged together and annotated. Both single and joint analysis were carried out using the 204 
EPACTS software
34
.  205 
SINGLE VARIANT ASSOCIATION TESTING 206 
The single variant logistic score test
34
 was performed in order to detect differences in variant 207 
frequency between cases and control group. The test was not performed on mutations occurring in one 208 
individual in either case or control group.  209 
 210 
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 211 
RARE VARIANT PROFILE FILTERING 212 
The burden of rare and novel damaging variation was described for each of the 18 patients across 49 213 
asthma genes. Synonymous variations were excluded from the analysis on the assumption of their low 214 
impact on protein function. All novel to individual, novel to Southampton PIBD cohort and clinical 215 
variants as well as frameshift insertion, frameshift deletion, stop gain and stop loss mutations were 216 
retained for further analysis. Novel to individual denotes variants not previously reported in  217 
dbSNP137 database, 1000 Genomes Project, Exome Variants Server (EVS) of European Americans 218 
in the NHLI-ESP project with 6500 exomes [http://evs.gs.washington.edu/EVS/], in 46 unrelated 219 
human subjects sequenced by Complete Genomics
65
, in other individuals of the Soton IBD cohort, or 220 
in the Southampton reference exome database. Novel to Soton cohort denotes variants not previously  221 
reported in dbSNP137 database
66
, 1000 Genomes Project
36
, Exome Variants Server (EVS) of 222 
European Americans in the NHLI-ESP project with 6500 exomes [http://evs.gs.washington.edu/EVS/], 223 
in 46 unrelated human subjects sequenced by Complete Genomics
65
 but has been seen in other 224 
individuals of the Soton IBD cohort. 225 
To refine this list to variations most likely to have a biological impact, common variants occurring in 226 
≥ 5% of individuals from 1000 genomes project35,36 were excluded and variants less likely to impact 227 
on protein function as expressed by the logit categorical score
37
were excluded (logit = N). Pathways 228 
were determined using DAVID (Database for Annotation, Visualization and Integrated Discovery;)
38
 229 
and KEGG pathway
39
. 230 
JOINT VARIANT ASSOCIATION TESTING 231 
The sequence kernel association testing optimal unified test (SKAT-O)
40
 is a gene-based test for 232 
assessing the contribution of rare and common variations within a genomic loci with trait
40
. 233 
Specifically, SKAT-O encompasses both a burden test and a SKAT
40
 test to offer a powerful way of 234 
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conducting association analysis on combined rare and common variation as single variant tests are 235 
often underpowered due to the large sample size needed to detect a significant association. 236 
SKAT-O was executed with the small sample adjustment and by applying a MAF threshold of 0.05 to 237 
define rare variations and using default weights. To conduct the test, a group file with mutations of 238 
interests (missense, nonsense, splice-site variants and coding indels) was created for each of the 49 239 
genes.  240 
ETHICAL CONSIDERATIONS 241 
The study has ethics approval from Southampton & South West Hampshire Research Ethics 242 
Committee (09/H0504/125). 243 
  244 
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Results 245 
SOUTHAMPTON PIBD COHORT 246 
At the time of analysis the Southampton PIBD study cohort comprised 173 children (98 CD, 55 UC 247 
and 20 IBDU); demographic data is shown in table 1. 248 
 249 
PREVALENCE OF COMORBIDITY  250 
Analysis of the cohort revealed concurrent diagnosis of PIBD with 12 distinct autoimmune mediated 251 
conditions (Table 2).  252 
Asthma (n=28) and atopic dermatitis (n=24) represented the conditions with the highest frequency. 253 
Additional cases of sclerosing cholangitis (n=4), coeliac disease (n=2) and vitiligo (n=2) were present.  254 
Forty nine children (28.3%) presented with a second autoimmune condition. Across the cohort there 255 
was a family history of asthma, atopic dermatitis, coeliac disease, sclerosing cholangitis and vitiligo 256 
although no probands had diagnosis of these conditions at the time of analysis. 257 
 258 
 SINGLE VARIANT ASSOCIATION TEST FOR VARIANTS IN ASTHMA AND DUAL SUSCEPTIBILITY GENES 259 
Among the 28 patients affected by asthma, 18 youngest patients were selected for exome sequencing 260 
(9 CD and 9 UC). Characteristics for each of the patients that underwent exome sequencing are 261 
presented in Table 3. Thirty-six of the 49 genes either specific to asthma and common to both asthma 262 
and IBD were analyzed, as no coding variants were called in ADRA1B, CCL5, CD14, HLA-DQ, 263 
IL12B, IL13, IL4, ORMDL3, PCDH1, RAD50, TNF, TSLP and SLC22A5 across cases and controls 264 
and these genes were excluded from single variant and joint testing.  265 
A total of 175 different variants were identified across 36 genes in the cases and controls exomes. 73 266 
occurred only in one individual (case or control) and these were not analyzed in the single variant test. 267 
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The single variant test was applied to 102 variants across 33 genes. Three of these variants showed 268 
significant association with disease status (association p <0.05; PYHIN1, ZPBP2 and LRRC32). 269 
However, none of these variants would withstand multiple testing corrections (Supplementary Table 270 
S2). ZPBP2 and LRRC32 are known to be involved in both asthma and IBD. Within these genes, 271 
ZPBP2 nonsynonymous variant at position 38027030 bp and LRRC32 synonymous variant at position 272 
76372052 bp (p= 0.011 and p=0.043 respectively) were found with higher frequency in cases 273 
compared to controls. PYHIN1 is known to be involved in asthma pathogenesis. In this gene the 274 
nonsynonymous variant at position 158943483bp (p= 0.008) was observed at higher frequency in 275 
cases compared to control group. The frequency of these mutations suggests their possible deleterious 276 
effect in increasing disease risk in genetically susceptible individuals.  277 
 278 
INDIVIDUAL PROFILES OF RARE AND DELETERIOUS VARIANTS 279 
Individual burden of variation revealed 24 variants (supplementary table S3). Several dual 280 
susceptibility genes (for PIBD and Asthma) were identified as harboring one or more variants. 281 
Mutations fall within 3 pathways consistently reported in KEGG and DAVID. ZPBP2 (zona pellucida 282 
binding protein 2
12
) and SMAD3 (involved in the adherens junction pathway
41
)  have variants 283 
observed across both CD and UC but these variants also occur in 1% and 2% of the 1000 Genomes 284 
reference population . 285 
Patient PR0085 carries the nonsynonymous ZPBP2 mutation, but also carries a novel frameshift 286 
deletion in DENND1B gene expressed by natural killer cells and dendritic cells
42,43
. The same patient 287 
harbors a nonsynonymous mutation at position 67353579 bp within GSTP1 which is reported to be 288 
involved in asthma pathogenesis only. Also of interest amongst the genes previously implicated in 289 
both diseases are two distinct and very rare mutations in the RAD50 gene located within the IBD5 290 
cytokine cluster on chromosome 5q31
44
. This gene contains the locus control region required for the 291 
Th2 cytokine gene expression
45
. In asthma specific genes, variations were found in 8 genes. A more 292 
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common variant (rs3918396) is seen to recur within the ADAM33 gene, a second variant in the same 293 
gene has been identified in PR0158 and other patients within the Southampton PIBD cohort. 294 
PR0110 is a patient diagnosed aged 2 years with severe UC. She is seen to harbor a mutation that 295 
could impact splicing at position 8009439 bp in GLCCI1 and a novel frameshift insertion at position 296 
69407255 within CTNNA3. This gene encodes the α –T-catenin  protein; a key component of the 297 
adherens junctional complex in epithelial cells necessary for cellular adherence
46
.  298 
 299 
JOINT RARE VARIANT ASSOCIATION TEST FOR VARIANTS IN IBD AND DUAL SUSCEPTIBILITY GENES 300 
The joint test for assessing the contribution of private, rare and common mutation between disease 301 
status and genes highlighted 6 genes with a p-value < 0.05 prior to Bonferroni correction (table 4). 302 
Of these 6 genes, 3 are known susceptibility genes for both IBD and asthma (ZPBP2 p= 0.009, IL1R1 303 
p= 0.036 and IL18R1 p= 0.038); the remaining genes were asthma specific (PYHIN p= 0.025;  IL2RB 304 
p=0.036; GSTP1 p= 0.040). These genes are all key determinants of the immune response and have 305 
variants observed across both CD and UC. 306 
 307 
 308 
 309 
 310 
 311 
 312 
 313 
 314 
 315 
 316 
 317 
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Discussion 318 
Our cohort of 173 children with PIBD revealed forty nine children (28.3%) with a concurrent 319 
diagnosis of an autoimmune disease. Asthma and atopic dermatitis occurred with the highest 320 
frequency; the prevalence of clinically diagnosed asthma was 19.4% in children with CD and 16.4% 321 
in patients with UC, exceeding UK disease estimates (15.3%
47,48
). 322 
Although this study is not powered to demonstrate a statistically significant increase in autoimmune 323 
disease burden in children with PIBD, our observations indicate prevalence estimates approaching the 324 
upper limit recorded in the literature
49
. Our findings are consistent with literature indicating children 325 
with PIBD are more likely to have other autoimmune conditions, and that a common genetic 326 
components etiology may predispose individuals to multiple autoimmune manifestations
20,29
. 327 
Even in a very modest cohort, SKAT-O association analysis revealed six genes with significant 328 
burden of mutation. While significant levels would not withstand a Bonferroni correction for 36 genes 329 
tested, the strong prior hypothesis to the analysis of these genes might suggest such a multiple testing 330 
correction would be inappropriate. 331 
ZPBP2 is located on the chr17q12-q21 region which has been associated with early-onset asthma, and 332 
variants in the same linkage disequilibrium block have been associated with Crohn's disease, type 1 333 
diabetes and primary biliary cirrhosis
50
.  334 
IL1R1 encodes for a cytokine receptor that belongs to the interleukin-1 receptor family. The gene was 335 
found associated with asthma in a GWAS on 933 European ancestry individuals with severe asthma 336 
based on Global Initiative for Asthma (GINA) criteria
51
. At the same genomic region of IL1R1, 337 
IL18R1 was also identified as associated with asthma. Specifically the gene was evaluated in a GWAS 338 
conducted on Mexican pediatrc patients
52
. The association was further replicated on a family-based 339 
study on Denmark, United Kingdom and Norway families
53
.  340 
GSTP1 is involved in the detoxification of a wide variety of exogenous and endogenous compounds, 341 
including reactive oxygen species. This gene was discovered by a GWAS conducted on early onset 342 
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asthma
54
. IL2RB is involved in lymphoid cell differentiation and it was firstly discovered by GWAS 343 
conducted by the GABRIEL consortium in 2012
55
. PYHIN1 (Pyrin And HIN Domain Family, 344 
Member 1) encodes a protein that belongs to the HIN-200 family of interferon inducible proteins, 345 
important in controlling cell cycle, differentiation and apoptosis
56
. It has been noted to be an asthma 346 
susceptibility locus, specifically in those of African descent
57
. PYHIN1 was identified as associated 347 
with asthma in 2011 through a meta-analysis conducted on 5,416 European American, African 348 
American or African Caribbean, and Latino ancestry individuals with asthma. The PYHIN1 349 
association was specific to the African descent groups
57
.  350 
PYHIN1 and ZPBP2 were significantly associated with asthma in both single variant testing and 351 
following SKAT-O testing. Variants within these genes were found with higher frequency in cases 352 
compared to controls suggesting a deleterious role of the mutations in the pathogenesis of disease. 353 
Susceptibility genes for both IBD and asthma are most commonly involved with immune regulation 354 
raising the possibility of an overall immune dysregulation underlying both diseases. These genes may 355 
be implicated in the same pathways as found in other probands but may not yet have been associated 356 
with IBD/asthma or did not hold enough significance power to be included in the GWAS meta-357 
analyses.  358 
 359 
This study demonstrates robust data collection, all PIBD diagnoses are made using strict criteria
21
  and 360 
autoimmune comorbidity was validated through integration of the medical notes (paper and 361 
electronic). This study looked only at genes identified through GWAS (of asthma and IBD) this 362 
increased the probability of finding causal rare and private mutation within known implicated genes. 363 
By design, GWAS are powered only to implicate genes in which common variant alleles are 364 
overrepresented in the disease population. It is highly likely that pathogenic coding changes that are 365 
either very rare or even private to individuals in other genes have gone undetected by these methods.  366 
17 
 
Exome sequencing allows capture of extremely large and useful amounts of data. Limitations of this 367 
sequencing technique still exist and can have an impact on research data; inefficiencies in the exon 368 
targeting process can lead to uneven capture and result in exons with low sequence coverage and off-369 
target hybridizations. Alongside this unknown or yet-to-be-annotated exons, evolutionary conserved 370 
non-coding regions and regulatory sequences (such as enhancers or promoters) involved in IBD and 371 
asthma will not be captured. Exome sequencing is not designed to capture information regarding the 372 
methylation state of DNA and therefore epigenetic factors in disease are not investigated. Necessary 373 
filtering of vast datasets intrinsic to NGS may lead to missed calling of valid variants.  374 
 375 
In this study, we identified the prevalence of concurrent autoimmune diagnoses in a cohort of children 376 
with childhood onset IBD. We observe a frequency of asthma and atopic dermatitis at the highest end 377 
of the normal range. In children with asthma we demonstrate that patient specific mutations in known 378 
disease-related genes are extensive and varied, even when restricted to mutations predicted to be 379 
pathogenic. NGS may be set to become a key routine diagnostic tool of the future, and it is important 380 
we begin to elucidate the role of key genes and pathways already known to us. Improved assessment 381 
of true functional significance of mutations will require substantial improvements to in silico 382 
annotation informed by rigorous and extensive functional validation of rare variants. However, perfect 383 
annotation of single variants in isolation cannot predict outcome in patients who harbor a profile of 384 
variants and across genes and pathways. This bottleneck to the interpretation of genomic data may be 385 
aided by assessment of highly selected patient groups
58
. Our study uncovers the patient specific 386 
burden of pathogenic mutations in known disease genes. We find evidence to support causality of key 387 
genes such as ZPBP2 and PYHIN1 and further postulate that for a subset of patients, the relationship 388 
between concurrent PIBD and autoimmune disease lies in systemic immune dysregulation rather than 389 
organ specific immune dysfunction.  390 
 391 
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Figures 550 
Figure 1: 551 
 552 
Overlap of GWAS significant gene loci in IBD, on the left, and asthma, on the right. 553 
 554 
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Tables  563 
Table 1: PIBD Cohort demographics. 564 
 565 
 566 
 567 
 568 
 569 
 570 
 571 
 572 
 573 
 574 
 575 
 576 
 577 
 578 
  Crohn's Disease Ulcerative 
colitis 
IBDU Total IBD 
Number of patients  98 55 20 173 
Female (%) 44 44 60 46 
Median  age of onset 
(25th/75th centile) 
12.28 
(9.16/14.27) 
11.5 
(9.61/13.48) 
15.33  
(8.72/14.10) 
12.28 
Mean age of onset (SD) 11.58 (3.13) 10.87 (3.76) 11.50 (3.31) 11.35 ( 3.35) 
25 
 
Table 2: Prevalence of autoimmune disease in the PIBD cohort (173 patients) 579 
Autoimmune 
disease 
Crohn's Disease 
(n = 98) 
 
Ulcerative 
Colitis (n = 55) 
 
IBDU 
(n= 20) 
 
Overall PIBD 
cohort 
prevalence 
(n=173) 
Overall Population 
pediatric 
prevalence (%) 
 
Asthma 19 (19.40%) 9 (16.40%) 0 28 (16.18%) 15.0030,59,60 
Atopic dermatitis 18 (18.40%) 6 (8.11%) 0 24 (13.87%) 16.5061 
Coeliac disease 1 (1.020%) 1 (1.35%) 0 2 (1.15%) 0.9962 
Sclerosing 
cholangitis 
1 (1.02%) 2 (3.64%) 1 (50%) 4 (2.31%) 0.01*63 
Vitiligo 1 (1.02%) 0 1 (50%) 2 (1.15%) 1.0064 
*
 Data for general population prevalence only and not specific to general IBD. 580 
 581 
 582 
 583 
 584 
 585 
 586 
 587 
 588 
 589 
 590 
 591 
 592 
 593 
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Table 3: Clinical profile of the 18 patients with concurrent IBD and asthma selected for exome 594 
analysis 595 
Study ID Sex Age at 
Diagnosis 
of IBD 
Diagnosis Paris classification 
of IBD 
Other autoimmune disease 
status other than asthma 
PR0007 M 11.41 CD A1L34B1  
PR0011 M 15.51 CD A1L1B2  
PR0031 M 11.43 CD A1L3B1p  
PR0032 M 7.29 CD A1L24B1p Atopic dermatitis 
PR0036 F 9.67 CD A1L3B1  
PR0039 M 10.30 UC E3-  
PR0068 F 11.23 UC E2-  
PR0083 F 9.68 UC E3S3  
PR0085 M 13.12 UC E3S3  
PR0107 M 9.22 CD A1L1-  
PR0110 F 2.98 UC E3-  
PR0146 M 14.52 CD A1L3-  
PR0148 M 9.13 CD A1L34B3p Atopic dermatitis 
PR0151 F 13.30 CD A1L24B1  
PR0158 F 15.25 UC E3S3 Atopic dermatitis 
PR0160 M 12.55 UC E3S1 Atopic dermatitis 
PR0167 M 13.30 UC E2S2 Atopic dermatitis 
PR0188 M 11.03 CD A1L1-  
- Denotes missing classification data. 596 
 597 
 598 
 599 
 600 
 601 
 602 
 603 
 604 
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Table 4: Joint variant test (SKAT-O) result for the 36 known asthma genes in which variations 605 
was found across the entire cohort. Only genes with a p<0.1 are shown.  606 
 607 
Gene set Gene Chr Bp position (hg19) 
Total 
number of 
samples 18 
cases; 56 
controls) 
Fraction of 
individuals who 
carry rare 
variants under 
the MAF 
thresholds 
(MAF < 0.05)* 
Number of 
all variants 
defined in 
the group 
file 
Number of 
variant 
defined as 
rare (MAF 
< 0.05)* 
P value 
unadjusted 
Asthma/IBD ZPBP2 17 38024626-38032996 74 0.027 4 1 0.009 
Asthma PYHIN1 1 158906777-158943483 74 0.108 5 5 0.025 
Asthma/IBD IL1R1 2 102781629-158943483 74 0.014 5 2 0.037 
Asthma IL2RB 22 37524329-37539651 74 0.014 4 1 0.037 
Asthma/IBD IL18R1 2 102984279-103001402 74 0.014 3 1 0.039 
Asthma GSTP1 11 67352183-67353970 74 0.014 4 1 0.041 
Asthma TLE4 9 82187750-82336794 74 0.108 4 4 0.056 
Asthma NPSR1 7 34698177-34917768 74 0.135 12 4 0.066 
Asthma  CTNNA3 10 67680203-69407255 74 0.162 6 3 0.081 
 608 
* These variants received different weights in the SKAT-O joint test.  609 
No variants were found in ADRA1B, CCL5, CD14, HLA-DQ, IL12B, IL13, IL4, ORMDL3, PCDH1, 610 
RAD50, TNF, TSLP and SLC22A5 across cases and controls. 611 
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Supplementary 612 
Table S1: Exome data quality statistics for eighteen concurrent IBD asthma patients. 613 
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PR0007 61168596 60439477 59932617 86.48 77.55 99.86 99.14 97.30 90.67 76.23 20 M 59.85 
PR0011 69670912 69051849 68552813 91.42 82.32 99.86 99.29 97.92 92.90 88.14 28 M 60.99 
PR0031 54550262 53889492 53477697 87.87 78.47 99.84 99.03 96.88 89.02 68.46 18 M 59.89 
PR0032 61891260 61170010 60697939 88.57 79.88 99.86 99.17 97.45 91.23 78.93 18 M 59.64 
PR0036 43600438 43332569 42984315 89.33 81.41 99.67 98.16 94.32 82.26 57.72 245 F 60.86 
PR0039 50980348 50646264 50195689 86.63 79.07 99.80 98.58 95.43 85.34 65.96 27 M 60.22 
PR0068 39114706 38536574 38207151 87.40 79.45 99.78 99.23 97.79 92.56 98.08 252 F 61.73 
PR0083 43560214 42854776 42452011 85.03 77.58 99.80 99.33 98.16 93.82 106.53 267 F 61.95 
PR0085 58398084 57615280 57206330 91.32 81.39 99.84 99.06 97.10 89.94 71.48 19 M 60.02 
PR0107 28699795 28550198 28262880 84.36 76.89 99.82 98.76 95.95 86.82 72.49 23 M 60.50 
PR0110 65421500 64811390 64250237 91.30 81.49 99.77 99.10 97.49 91.44 78.40 229 F 61.17 
PR0146 37280008 37021161 36686018 86.57 78.98 99.86 99.22 97.61 91.96 94.78 23 M 59.99 
PR0148 42605042 40826661 40411155 84.21 77.20 99.88 99.31 97.87 92.77 102.51 31 M 60.77 
PR0151 43335016 43029829 42634413 86.07 78.24 99.80 99.35 98.21 94.03 109.44 269 F 61.08 
PR0158 51702888 51360929 50940429 89.10 80.82 99.70 98.56 95.65 86.00 67.09 220 F 60.58 
PR0160 54556114 54187984 53702988 88.11 80.32 99.81 98.69 95.79 86.39 70.34 29 M 61.26 
PR0167 55264388 54888215 54452943 90.61 82.14 99.83 98.76 95.97 86.55 68.89 29 M 60.67 
PR0188 62180148 61748635 61191406 87.84 79.98 99.84 99.01 96.90 89.63 80.64 29 M 60.91 
 614 
Total no. read seqs- total number of reads sequenced; Total no. aligned reads - the total number of reads aligned to the reference sequence; Total no. unique 615 
align- the number of reads that uniquely mapped to the reference sequence; Mapped to target reads +/-150bp (%)- the percentage of reads mapped ±150 base 616 
pair to the target; Mapped to target reads (%)- the percentage of reads mapped to the target sequence; Target bases with coverage >1,5,10,20- the percentage 617 
of targets with 1, 5, 10 and 20 read depth; Mean coverage - the mean of the depth coverage; X heterozygosity - calls mapped to X chromosome heterozygous; 618 
Inferred Gender – apparent gender based upon X heterozygosity; % Genome-wide heterozygosity – genome wide % of calls heterozygous. 619 
 620 
 621 
 622 
 623 
  
29 
Andreoletti et al 
Table S2: Single variant test results for the 36 known asthma genes in which variation was 624 
found across the cohort. Only variants with a p<0.1 are shown. 625 
Gene set Gene Chr Bp position 
(hg19) 
Var MAF in the 
cohort 
Allele 
frequency in 
cases  
Allele 
frequency in 
controls 
P value 
unadjusted 
Asthma/IBD ZPBP2 17 38027030 ns 0.014 0.056 0 0.011 
Asthma PYHIN1 1 158943483 ns 0.027 0.083 0.009 0.015 
Asthma/IBD LRRC32 11 76372052 sn 0.425 0.722 0.527 0.044 
Asthma/IBD SMAD3 15 67457698 ns 0.034 0.083 0.018 0.054 
Asthma NPSR1 7 34917768 ns 0.034 0.083 0.018 0.056 
Asthma IL6R 1 154426970 ns 0.419 0.556 0.375 0.07 
Asthma/IBD SMAD3 15 67457335 ns 0.135 0.944 0.839 0.08 
Asthma PYHIN1 1 158908886 ns 0.02 0.056 0.009 0.081 
Asthma NPSR1 7 34917702 ns 0.108 0.028 0.134 0.097 
 626 
*Found 175 variant in 36 genes. 76 variant were removed because occurring in 1 individual in both 627 
cases and controls. 628 
 No variants in ADRA1B, CCL5, CD14, HLA-DQ, IL12B, IL13, IL4, ORMDL3, PCDH1, RAD50, TNF, 629 
TSLP and SLC22A5. 630 
 ns, nonsynonymous and sn, synonymous 631 
 632 
 633 
 634 
 635 
 636 
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Table S3: Deleterious variant profiles across asthma genes for all 18 patients with either CD or UC 637 
 638 
 639 
31 
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 640 
Cross (X) indicates presence of a variant 641 
ns, nonsynonymous; sn, synonymous; fi, frameshift insertion, fd, frameshift deletion; sp, splicing; nfi, 642 
non-frameshift insertion; nfd, non-frameshift deletion. 643 
*NtI (novel to individual) denotes variants not previously  reported in  dbSNP137 database, 1000 644 
Genomes Project, Exome Variants Server (EVS) of European Americans in the NHLI-ESP project 645 
with 6500 exomes[http://evs.gs.washington.edu/EVS/], in 46 unrelated human subjects sequenced by 646 
Complete Genomics
65
, in other individuals of the Soton IBD cohort, or in the Southampton reference 647 
exome database. 648 
NtSC (novel to Soton cohort) denotes variants not previously  reported in  dbSNP137 database
66
, 1000 649 
Genomes Project
36
, Exome Variants Server (EVS) of European Americans in the NHLI-ESP project 650 
with 6500 exomes[http://evs.gs.washington.edu/EVS/], in 46 unrelated human subjects sequenced by 651 
Complete Genomics
65
 but has been seen in other individuals of the Soton IBD cohort. 652 
CS (Clinical significance) assigned dbSNP value of probable-pathogenic or pathogenic
66
. 653 
Pathways: ① Adherens junction67, ②Jak-STAT signaling pathway67 and ③Cytokine-cytokine 654 
receptor interaction
67
. 655 
 656 
 657 
 658 
 659 
  
